{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:41:18Z","timestamp":1793209278774,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1038\/s41401-020-00505-3","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T11:02:38Z","timestamp":1598526158000},"page":"814-823","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma"],"prefix":"10.1038","volume":"42","author":[{"given":"Xiao-tuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-bei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-juan","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-qi","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-biao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-hui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-cheng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-mei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-bo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"key":"505_CR1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503\u201311.","journal-title":"Nature"},{"key":"505_CR2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminhematol.2015.01.005","volume":"52","author":"L Pasqualucci","year":"2015","unstructured":"Pasqualucci L, Dalla-Favera R. The genetic landscape of diffuse large B-cell lymphoma. Semin Hematol. 2015;52:67\u201376.","journal-title":"Semin Hematol"},{"key":"505_CR3","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922\u20136.","journal-title":"Nat Med"},{"key":"505_CR4","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized phase III trial of ibrutinib and plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-Cell lymphoma. J Clin Oncol. 2019;37:1285\u201395.","journal-title":"J Clin Oncol"},{"key":"505_CR5","unstructured":"IMBRUVICA (ibrutinib). Prescribing information. Horsham, PA: Janssen Biotech; Sunnyvale, CA: Pharmacyclics; 2018."},{"key":"505_CR6","volume-title":"Summary of product characteristics","author":"IMBRUVICA (ibrutinib)","year":"2018","unstructured":"IMBRUVICA (ibrutinib). Summary of product characteristics. Beerse, Belgium: Janssen Pharmaceutical NV; 2018."},{"key":"505_CR7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","volume":"14","author":"RW Hendriks","year":"2014","unstructured":"Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton\u2019s tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14:219\u201332.","journal-title":"Nat Rev Cancer"},{"key":"505_CR8","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3109\/10428194.2015.1113276","volume":"57","author":"JH Kim","year":"2016","unstructured":"Kim JH, Kim WS, Ryu K, Kim SJ, Park C. CD79B limits response of diffuse large B cell lymphoma to ibrutinib. Leuk Lymphoma. 2016;57:1413\u201322.","journal-title":"Leuk Lymphoma"},{"key":"505_CR9","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-2158-0","volume":"10","author":"I Kapoor","year":"2019","unstructured":"Kapoor I, Li Y, Sharma A, Zhu H, Bodo J, Xu W, et al. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K\/AKT activation in B-cell lymphoid malignancies. Cell Death Dis. 2019;10:924.","journal-title":"Cell Death Dis"},{"key":"505_CR10","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1158\/1535-7163.MCT-16-0555","volume":"16","author":"H-P Kuo","year":"2017","unstructured":"Kuo H-P, Ezell SA, Schweighofer KJ, Cheung LWK, Hsieh S, Apatira M, et al. Combination of ibrutinib and ABT-199 in diffuse large B-cell lymphoma and follicular lymphoma. Mol Cancer Ther. 2017;16:1246\u201356.","journal-title":"Mol Cancer Ther"},{"key":"505_CR11","first-page":"2489","volume":"6","author":"K Hsu-Ping","year":"2016","unstructured":"Hsu-Ping K, Scott AE, Sidney H, Karl JS, Leo WKC, Shiquan W. et al. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma. Am J Cancer Res. 2016;6:2489\u2013501.","journal-title":"Am J Cancer Res"},{"key":"505_CR12","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment\/Map format and SAMtools. Bioinformation. 2009;25:2078\u20139.","journal-title":"Bioinformation"},{"key":"505_CR13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213\u20139.","journal-title":"Nat Biotechnol"},{"key":"505_CR14","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","volume":"28","author":"CT Saunders","year":"2012","unstructured":"Saunders CT, Wong WS, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics. 2012;28:1811\u20137.","journal-title":"Bioinformatics"},{"key":"505_CR15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/bioinformatics\/btr670","volume":"28","author":"V Boeva","year":"2012","unstructured":"Boeva V, Popova T, Bleakley K, Chiche P, Cappo J, Schleiermacher G, et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics. 2012;28:423\u20135.","journal-title":"Bioinformatics"},{"key":"505_CR16","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"505_CR17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101\u20138.","journal-title":"Nat Protoc"},{"key":"505_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4528","volume":"5","author":"M Shao","year":"2014","unstructured":"Shao M, Shan B, Liu Y, Deng Y, Yan C, Wu Y, et al. Hepatic IRE1alpha regulates fasting-induced metabolic adaptive programs through the XBP1s-PPARalpha axis signalling. Nat Commun. 2014;5:3528.\u00a0https:\/\/doi.org\/10.1038\/ncomms4528.","journal-title":"Nat Commun"},{"key":"505_CR19","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","volume":"33","author":"A Ianevski","year":"2017","unstructured":"Ianevski A, He L, Aittokallio T, Tang J. Synergy-Finder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics. 2017;33:2413\u20135.","journal-title":"Bioinformatics"},{"key":"505_CR20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88\u201392.","journal-title":"Nature"},{"key":"505_CR21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bjh.13427","volume":"170","author":"SQ Zhang","year":"2015","unstructured":"Zhang SQ, Smith SM, Zhang SY, Lynn Wang Y. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2015;170:445\u201356.","journal-title":"Br J Haematol"},{"key":"505_CR22","first-page":"61","volume":"126","author":"TM Liu","year":"2015","unstructured":"Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, et al. Hypermorphic mutation of phospholipase C, gamma2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood. 2015;126:61\u20138.","journal-title":"Blood"},{"key":"505_CR23","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1182\/bloodadvances.2018016048","volume":"2","author":"L Jimmy","year":"2018","unstructured":"Jimmy L, Zhang LL, Wu W, Guo H, Li Y, Sukhanova M, et al. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in MCL. Blood Adv. 2018;2:2039\u201351. https:\/\/doi.org\/10.1182\/bloodadvances.2018016048.","journal-title":"Blood Adv"},{"key":"505_CR24","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A, et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med. 2014;370:2352\u20134.","journal-title":"N Engl J Med"},{"key":"505_CR25","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","volume":"4","author":"D Chiron","year":"2014","unstructured":"Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014;4:1022\u201335.","journal-title":"Cancer Discov"},{"key":"505_CR26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/17474086.2018.1435268","volume":"11","author":"BL Lampson","year":"2018","unstructured":"Lampson BL, Brown JR. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? Expert Rev Hematol. 2018;11:185\u201394.","journal-title":"Expert Rev Hematol"},{"key":"505_CR27","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1182\/blood-2017-10-811752","volume":"131","author":"JG Chen","year":"2018","unstructured":"Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, et al. BTK (Cys481Ser) drives ibrutinib resistance via ERK1\/2 and protects BTK (wild-type) MYD88-mutated cells by a paracrine mechanism. Blood. 2018;131:2047\u201359.","journal-title":"Blood"},{"key":"505_CR28","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0092-8674(01)00611-0","volume":"107","author":"H Yoshida","year":"2001","unstructured":"Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell. 2001;107:881\u201391.","journal-title":"Cell"},{"key":"505_CR29","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1172\/JCI95864","volume":"128","author":"H Xie","year":"2018","unstructured":"Xie H, Tang CH, Song JH, Mancuso A, Del Valle JR, Cao J, et al. IRE1alpha RNase-dependent lipid homeostasis promotes survival in Myc-transformed cancers. J Clin Invest. 2018;128:1300\u201316.","journal-title":"J Clin Invest"},{"key":"505_CR30","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1172\/JCI95873","volume":"128","author":"N Zhao","year":"2018","unstructured":"Zhao N, Cao J, Xu L, Tang Q, Dobrolecki LE, Lv X, et al. Pharmacological targeting of MYC-regulated IRE1\/XBP1 pathway suppresses MYC-driven breast cancer. J Clin Invest. 2018;128:1283\u201399.","journal-title":"J Clin Invest"},{"key":"505_CR31","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1158\/1078-0432.CCR-15-1570","volume":"22","author":"JR Cubillos-Ruiz","year":"2016","unstructured":"Cubillos-Ruiz JR, Bettigole SE, Glimcher LH. Molecular pathways: immunosuppressive roles of IRE1alpha-XBP1 signaling in dendritic cells of the tumor microenvironment. Clin Cancer Res. 2016;22:2121\u20136.","journal-title":"Clin Cancer Res"},{"key":"505_CR32","doi-asserted-by":"crossref","first-page":"40692","DOI":"10.18632\/oncotarget.5827","volume":"6","author":"J Ming","year":"2015","unstructured":"Ming J, Ruan S, Wang M, Ye D, Fan N, Meng Q, et al. A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1\/XBP1. Oncotarget. 2015;6:40692\u2013703.","journal-title":"Oncotarget"},{"key":"505_CR33","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1096\/fj.06-7990com","volume":"21","author":"BP Gomez","year":"2007","unstructured":"Gomez BP, Riggins RB, Shajahan AN, Klimach U, Wang A, Crawford AC, et al. Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J. 2007;21:4013\u201327.","journal-title":"FASEB J"},{"key":"505_CR34","doi-asserted-by":"crossref","first-page":"16420","DOI":"10.1073\/pnas.1906999116","volume":"116","author":"JM Harnoss","year":"2019","unstructured":"Harnoss JM, Le Thomas A, Shemorry A, Marsters SA, Lawrence DA, Lu M, et al. Disruption of IRE1alpha through its kinase domain attenuates multiple myeloma. Proc Natl Acad Sci USA. 2019;116:16420\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"505_CR35","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1182\/blood-2011-07-366633","volume":"119","author":"N Mimura","year":"2012","unstructured":"Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, et al. Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma. Blood. 2012;119:5772\u201381.","journal-title":"Blood"},{"key":"505_CR36","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1172\/JCI73448","volume":"124","author":"CH Tang","year":"2014","unstructured":"Tang CH, Ranatunga S, Kriss CL, Cubitt CL, Tao J, Pinilla-Ibarz JA, et al. Inhibition of ER stress-associated IRE-1\/XBP-1 pathway reduces leukemic cell survival. J Clin Invest. 2014;124:2585\u201398.","journal-title":"J Clin Invest"},{"key":"505_CR37","doi-asserted-by":"crossref","first-page":"14428","DOI":"10.18632\/oncotarget.24467","volume":"9","author":"Y Tanabe","year":"2018","unstructured":"Tanabe Y, Suehara Y, Kohsaka S, Hayashi T, Akaike K, Mukaihara K, et al. IRE1alpha-XBP1 inhibitors exerted anti-tumor activities in Ewing\u2019s sarcoma. Oncotarget. 2018;9:14428\u201343.","journal-title":"Oncotarget"},{"key":"505_CR38","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3324\/haematol.2011.043331","volume":"97","author":"SC Ling","year":"2012","unstructured":"Ling SC, Lau EK, Al-Shabeeb A, Nikolic A, Catalano A, Iland H, et al. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica. 2012;97:64\u201372.","journal-title":"Haematologica"},{"key":"505_CR39","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.1038\/bcj.2016.40","volume":"6","author":"N Nikesitch","year":"2016","unstructured":"Nikesitch N, Tao C, Lai K, Killingsworth M, Bae S, Wang M, et al. Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response. Blood Cancer J. 2016;6:e432.","journal-title":"Blood Cancer J"},{"key":"505_CR40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","volume":"24","author":"C Leung-Hagesteijn","year":"2013","unstructured":"Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013;24:289\u2013304.","journal-title":"Cancer Cell"},{"key":"505_CR41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.0105-2896.2006.00373.x","volume":"210","author":"AL Shaffer","year":"2006","unstructured":"Shaffer AL, Wright G, Yang L, Powell J, Ngo V, Lamy L, et al. A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev. 2006;210:67\u201385.","journal-title":"Immunol Rev"},{"key":"505_CR42","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2016-09-741348","volume":"129","author":"B Bujisic","year":"2017","unstructured":"Bujisic B, De Gassart A, Tallant R, Demaria O, Zaffalon L, Chelbi S, et al. Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth. Blood. 2017;129:2420\u20138.","journal-title":"Blood"},{"key":"505_CR43","doi-asserted-by":"crossref","first-page":"27905","DOI":"10.1074\/jbc.M702672200","volume":"282","author":"SF de Almeida","year":"2007","unstructured":"de Almeida SF, Picarote G, Fleming JV, Carmo-Fonseca M, Azevedo JE, de Sousa M. Chemical chaperones reduce endoplasmic reticulum stress and prevent mutant HFE aggregate formation. J Biol Chem. 2007;282:27905\u201312.","journal-title":"J Biol Chem"},{"key":"505_CR44","first-page":"294","volume":"73","author":"ZWJ Li","year":"2018","unstructured":"Li ZWJ, Sheng L. Ibrutinib improves the development of acute lymphoblastic leukemia by activating endoplasmic reticulum stress-induced cell death. Pharmazie. 2018;73:294\u20139.","journal-title":"Pharmazie"},{"key":"505_CR45","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood-2014-04-567198","volume":"124","author":"S Krysov","year":"2014","unstructured":"Krysov S, Steele AJ, Coelho V, Linley A, Sanchez Hidalgo M, Carter M, et al. Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK. Blood. 2014;124:3101\u20139.","journal-title":"Blood"},{"key":"505_CR46","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00280-010-1391-0","volume":"67","author":"HKM Xi","year":"2011","unstructured":"Xi HKM, Liu H, Wangpaichitr M, You M, Liu X, Savaraj N, et al. 2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemother Pharmacol. 2011;67:899\u2013910.","journal-title":"Cancer Chemother Pharmacol"},{"key":"505_CR47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.canlet.2015.02.029","volume":"360","author":"H Huang","year":"2015","unstructured":"Huang H, Liu H, Liu C, Fan L, Zhang X, Gao A, et al. Disruption of the unfolded protein response (UPR) by lead compound selectively suppresses cancer cell growth. Cancer Lett. 2015;360:257\u201368.","journal-title":"Cancer Lett"},{"key":"505_CR48","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1016\/j.bbagen.2013.07.010","volume":"1830","author":"LX Fan","year":"2013","unstructured":"Fan LX,\u00a0Liu CM,\u00a0Gao AH,\u00a0Zhou YB,\u00a0Li J. Berberine combined with 2-deoxy-D-glucose synergistically enhances cancer cell proliferation inhibition via energy depletion and unfolded protein response disruption. Biochim Biophys Acta. 2013;1830:5175\u201383.","journal-title":"Biochim Biophys Acta"},{"key":"505_CR49","doi-asserted-by":"crossref","first-page":"26046","DOI":"10.18632\/oncotarget.25433","volume":"9","author":"F Lucantoni","year":"2018","unstructured":"Lucantoni F, Dussmann H, Llorente-Folch I, Prehn JHM. BCL2 and BCL(X)L selective inhibitors decrease mitochondrial ATP production in breast cancer cells and are synthetically lethal when combined with 2-deoxy-D-glucose. Oncotarget. 2018;9:26046\u201363.","journal-title":"Oncotarget"},{"key":"505_CR50","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1124\/dmd.111.039164","volume":"39","author":"J Yang","year":"2011","unstructured":"Yang J,\u00a0Wang Z,\u00a0Fang Y,\u00a0Jiang J,\u00a0Zhao F,\u00a0Wong H. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos. 2011;39:1873\u201382.","journal-title":"Drug Metab Dispos"},{"key":"505_CR51","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1034\/j.1600-065X.2000.00605.x","volume":"176","author":"T Kurosaki","year":"2000","unstructured":"Kurosaki T, Maeda A, Ishiai M, Hashimoto A, Inabe K, Takata M. Regulation of the phospholipase C-gamma2 pathway in B cells. Immunol Rev. 2000;176:19\u201329.","journal-title":"Immunol Rev"},{"key":"505_CR52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ceca.2017.08.004","volume":"70","author":"A Carreras-Sureda","year":"2018","unstructured":"Carreras-Sureda A, Pihan P, Hetz C. Calcium signaling at the endoplasmic reticulum: fine-tuning stress responses. Cell Calcium. 2018;70:24\u201331.","journal-title":"Cell Calcium"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00505-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00505-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00505-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T23:26:28Z","timestamp":1630020388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00505-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["505"],"URL":"https:\/\/doi.org\/10.1038\/s41401-020-00505-3","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,27]]},"assertion":[{"value":"24 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}